Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 11:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 5,570 matching trials from the live ClinicalTrials.gov search.
Conditions
Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions
Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Positron-Emission Tomography, Metastatic Solid Tumors
Interventions
⁸⁹Zr-Df-IAB22M2C
Drug
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more
Conditions
Solid Tumor, Advanced Solid Tumor
Interventions
M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW, M4344 80 mg BIW, M4344 160 mg BIW, M4344 300 mg BIW, M4344 450 mg BIW, M4344 700 mg BIW, M4344 1050 mg BIW, M4344 1200 mg BIW, M4344 100 mg BID, M4344 150 mg QD, M4344 250 mg QD, M4344 350 mg QD, M4344 400 mg, M4344 500 mg, Carboplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
8
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • St Louis, Missouri + 4 more
Conditions
Thyroid Cancer, Thyroid Nodule, Thyroid Neoplasms, Thyroid Goitre, Thyroid Diseases, Parathyroid Diseases, Parathyroid Adenoma, Parathyroid Hyperplasia
Interventions
Acetaminophen 500Mg Cap, Tylenol #3 Oral Tablet, Tramadol
Drug
Lead sponsor
Minerva A Romero Arenas
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Edinburg, Texas
Conditions
Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions
MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
21 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Cytoreductive Nephrectomy, Active Comparator
Procedure · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
387
States / cities
Birmingham, Alabama • Gilbert, Arizona • Kingman, Arizona + 262 more
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, EFV/FTC/TDF, RTV, ATV, FTC/TDF, COBI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
91
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 59 more
Conditions
HIV Infections
Interventions
Antiretroviral therapy
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
16 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Modakafusp alfa, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Pomalidomide, Elotuzumab, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
Interventions
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
19
States / cities
Little Rock, Arkansas • San Francisco, California • Stanford, California + 13 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of ALO-02 and OxyContin

NCT01557257
Conditions
Management of Moderate to Severe Pain
Interventions
ALO-02, Naltrexone block, OxyContin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Posttraumatic Stress Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Osteosarcoma, Metastasis
Interventions
Methotrexate, Doxorubicin, Cisplatin, Gefitinib, Trametinib, Disulfiram, Sunitinib, Ifosfamide, Biopsy
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
6 Years to 49 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)

NCT02823028
Conditions
Smoking Cessation
Interventions
NRT, Web Guide, Tweet2Quit
Drug · Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 59 Years
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Irvine, California • Stanford, California
Conditions
Stutter, Stuttering, Adult, Stuttering, Stuttering, Developmental
Interventions
Speech Production During functional magnetic resonance imaging (MRI)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
Interventions
Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars), Birinapant, Venetoclax, Gemcitabine, Docetaxel, Azacitidine
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Combined MRI and Optical Imaging to Improved Breast Cancer Diagnosis

NCT00610467
Conditions
Breast Cancer
Interventions
Disease Group, Control Group
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Irvine, California
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, CBZ
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Biliary Tract Cancer (BTC)
Interventions
D07001-Softgel Capsules, Placebo, Capecitabine
Drug · Combination Product
Lead sponsor
InnoPharmax Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Tucson, Arizona • Miami Beach, Florida • Cleveland, Ohio + 1 more
Conditions
Arthritis, Pain, Cognitive Impairment
Interventions
long acting oxycodone, extra strength acetaminophen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Aldesleukin, Cyclophosphamide, Decitabine, Genetically Engineered NY-ESO-1-specific T Lymphocytes, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional

Guidelines for Acute Sinusitis

NCT00132275
Conditions
Sinusitis
Interventions
Amoxicillin potassium clavulanate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
1 Year to 10 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania